Bloomberg Expert Highlights 5 Biotech Stocks Rethinking Diabetes: Avant Technologies, Novo Nordisk, Eledon, Viking, and Tandem Diabetes Care

Avant Technologies, Novo Nordisk, Eledon Pharmaceuticals, Viking Therapeutics, and Tandem Diabetes Care are rethinking diabetes with a focus on curative platforms over symptom-management franchises. Recent clinical trials have achieved 83% insulin independence rates, and the regenerative medicine market is projected to surge from $37.98 billion in 2025 to $88.85 billion by 2030. Avant is developing cell-based therapies for diabetes, aging, and chronic diseases using a proprietary encapsulation technology that protects genetically modified therapeutic cells from immune rejection.